跳至主要内容
临床试验/NCT02152800
NCT02152800已完成4 期

A Study of Vacyless® Versus Valtrex® in Patients With Herpes Zoster

Yung Shin Pharm. Ind. Co., Ltd.1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2011年4月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
4 期
状态
已完成
入组人数
25
试验地点
1
主要终点
the rash severity, in terms of rash counts

研究概览

简要总结

The purpose of this study is to compare the safety and efficacy of Vacyless® and Valtrex® in patients with acute herpes zoster.

详细描述

Primary Endpoint:

  • Lesion assessment - Rash severity, in terms of rash counts

Secondary Endpoints:

  • Pain assessment
  • Clinical global impression
  • Safety information of valacyclovir

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
20 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Men and women between 20 to 80 years of age.
  • Patients with a clinical diagnosis of HZ as evidenced by a unilateral dermatomal rash.
  • Patients with zoster-related rash (rash severity is greater than or equal to mild).
  • Patients are able to be enrolled into the study 72 hours from appearance of rash (for example, lesions or vesicles).
  • Patients provided written informed consent.
  • Patients who are able to complete all study visits per protocol.
  • Men and premenopausal women must agree to practice a barrier method of birth control or the use of a spermicide for one month after the last dose of study drug (oral contraceptives are not permitted). Subject should be withdrew from the study if contraceptions are faild.

排除标准

  • Women who are pregnant or lactating.
  • Patients with multidermatomal or disseminated HZ (greater than 20 lesions beyond the dermatomes adjacent to the primarily involved dermatome).
  • Patients with HZ ophthalmicus, defined as cutaneous lesions in the dermatome associated with the ophthalmic division of the trigeminal nerve
  • Patients with history of impaired renal function, (e.g., calculated creatinine clearance less than 50 mL/min/1.73 m2)
  • Patients are taking narcotic analgesic routinely for a chronic pain condition
  • Patients are taking tricyclic antidepressants
  • Patients who received systemic antivirals with activity against VZV within the past 30 days, or a topical antiviral to treat their current HZ
  • Patients with immunosuppressive or immunodeficient condition resulting from:
  • disease (e.g., HIV) corticosteroid use (except intermittent or topical/inhaled beclomethasone dipropionate or equivalent < 800 mcg/day), or other immunosuppressive/cytotoxic therapy (cancer chemotherapy or organ transplantation )
  • Patients with any other condition (e.g., extensive psoriasis, chronic pain syndrome, cognitive impairment) that, in the opinion of the site investigator, might interfere with the evaluations required by the study
  • Patients who are not ambulatory (bed-ridden or homebound); hospitalized patients may be enrolled if they are ambulatory and able to complete the study requirements
  • Patients with history of allergy to valacyclovir hydrochloride and acetaminophen
  • Patients are unlikely to adhere to protocol follow-up

研究组 & 干预措施

Valtrex® 500 mg

Active Comparator

Two Valtrex® 500 mg tablets, 3 times daily for 7days

干预措施: valacyclovir hydrocholoride (Drug)

Vacyless® 1000 mg

Experimental

one Vacyless® 1000 mg tablets, 3 times daily for 7days

干预措施: valacyclovir hydrocholoride (Drug)

Vacyless® 500mg

Experimental

Two Vacyless® 500mg tablets, 3 times daily for 7 days

干预措施: valacyclovir hydrocholoride (Drug)

结局指标

主要结局

the rash severity, in terms of rash counts

时间窗: Day 28

次要结局

  • VAS Pain score(Day 28)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验